Vetoquinol
Research Vetoquinol (VETO) on Bullrun: market cap EUR 855.57M, P/E 13.5, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVETO
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 855.57M
- P/E13.5
- Dividend yield1.2%
- Financial periodFY2025
- RevenueEUR 525.69M
- Revenue growth-2.5%
- Net incomeEUR 57.36M
- Free cash flowEUR 51.35M
- Gross margin74.7%
Valuation Snapshot
latest market cap is EUR 855.57M; P/E is 13.5; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 13.53x versus a Healthcare sector median of 24.67x (45.2% below).
Latest dividend yield is 1.22% versus a Healthcare sector median of 1.84% (33.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 525.69M | EUR 57.36M | EUR 51.35M | 74.7% | 4.94 | EUR 221.08M | EUR 15.29M | EUR 591.37M |
| FY2024 | EUR 539.20M | EUR 58.69M | EUR 68.15M | 71.9% | 4.98 | EUR 206.33M | EUR 21.12M | EUR 575.84M |
| FY2023 | EUR 529.27M | EUR 55.56M | EUR 70.38M | 70.4% | 4.7 | EUR 147.46M | EUR 17.63M | EUR 527.01M |
| FY2022 | EUR 539.78M | EUR 48.00M | EUR 40.36M | 70.4% | 4.06 | EUR 93.71M | EUR 17.42M | EUR 484.57M |
| FY2021 | EUR 521.27M | EUR 62.86M | EUR 57.31M | 71.1% | 5.31 | EUR 69.00M | EUR 15.38M | EUR 441.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | EUR 855.57M | 13.5 | 1.3% | 0.93 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.93 EUR, yield 1.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.89 EUR |
| FY2024 | 0.85 EUR |
| FY2023 | 0.8 EUR |
| FY2022 | 0.8 EUR |
| FY2021 | 0.5 EUR |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vetoquinol's market cap?
Vetoquinol's market capitalization is EUR 855.57M.
What is Vetoquinol's P/E ratio?
Vetoquinol's price-to-earnings (P/E) ratio is 13.5.
Does Vetoquinol pay a dividend?
Vetoquinol has a dividend yield of 1.2%.
What does Vetoquinol do?
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.